search
Back to results

Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III

Primary Purpose

Prostatitis

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Viagra (sildenafil citrate)
Sponsored by
University of Washington
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prostatitis focused on measuring Prostatitis

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of male Chronic Pelvic Pain Syndrome Type III Age 18 - 65 Pelvic pain duration of at least 3 months Exclusion Criteria: Urinary tract infection within the last year Sexually transmitted disease within 3 months Antiviral therapy or antibiotics within the last 3 months Currently taking any medications or recreational drugs containing nitrates 3A4 inhibitors such as erythromycin, ketoconazole, or itraconazole Alpha-blocker therapy for treatment of high blood pressure or prostate problems Suffered a heart attack, stroke or life-threatening arrhythmia within the last months Cardiac failure or coronary artery disease causing unstable angina Resting hypotension (BP<90/50) or hypertension (BP>170/110) Patients with retinitis pigmentosa Kidney, liver or blood problems (including sickle cell anemia or leukemia) Allergy to sildenafil Deformed penis, Peyronie's disease or ever having had an erection lasting more than 4 hours Stomach ulcers or any types of bleeding problems Use of any other medical treatments that cause erections: pills, medicines that are injected or inserted into the penis, implants or vacuum pumps Back pain, unilateral testicular pain or rectal pain only Post-surgical pain Prostate biopsy or cystoscopy within 3 months Pain from another source in the genital tract, such as kidney stones or neoplasm History of prostate, bladder, renal or other urinary malignancies History of intravesical Bacillus Calmette-Guerin (BCG) Ulcerative colitis or Crohn's disease Radiation therapy to pelvis History of genitourinary tuberculosis Any neurological abnormalities including spinal cord injury and stroke Overtly psychotic or suicidal Unable to understand the protocol In addition, subjects will be asked to refrain from having any new treatment for prostatitis during the study period, but will be allowed to remain on stable chronic therapy that they have been receiving for 3 or more months

Sites / Locations

  • University of Washington, Urology Clinic

Outcomes

Primary Outcome Measures

NIH-CPSI -pain scores at 3 and 12 month post tx follow-up
AUA Score - at 3 and 12 month post tx follow-up

Secondary Outcome Measures

Graded Chronic Pain Scale (GCPS)-3 & 12 mo post tx f/u

Full Information

First Posted
September 13, 2005
Last Updated
October 21, 2008
Sponsor
University of Washington
Collaborators
Berger, Richard E., M.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT00194597
Brief Title
Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III
Official Title
Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III
Study Type
Interventional

2. Study Status

Record Verification Date
October 2008
Overall Recruitment Status
Terminated
Why Stopped
Illness of PI forced termination.
Study Start Date
July 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2007 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University of Washington
Collaborators
Berger, Richard E., M.D.

4. Oversight

5. Study Description

Brief Summary
Viagra is a potent 5-PDE inhibitor that causes vasodilation in the penis and, therefore, erection in men with erectile dysfunction. Our hypothesis is that Viagra may improve the symptoms of men with Chronic Pelvic Pain Syndrome based on the following assumptions: Chronic Pelvic Pelvic Syndrome and Interstitial Cystitis involve poorly understood central and peripheral pain sensitization such as are seen in Chronic Sympathetic Dystrophy, also called Chronic Regional Pain Syndrome. This pain may be caused by constricted blood vessels resulting from past stress, injury or trauma Viagra will dilate sympathetically constricted vessels and improve pelvic blood flow in the same manner it does in men with erectile dysfunction. Since men with Chronic Pelvic Pain Syndrome often complain of sexual dysfunction; improving sexual function and, therefore, quality of life may improve overall well being and perception of pain.
Detailed Description
Screening Visit (Visit 1): Patient will review and sign the study consent form. They will then be asked to complete study questionnaires regarding demographics, medical history, pelvic pain and psychological issues. Urine will be collected and cultured for bacteria, gonorrhea and chlamydia . It will also be analyzed for white blood cells, NO and chemistry. There will be a physical exam and prostate massage. During the prostate massage, expressed prostatic secretions will be collected and sent to the Male Fertility Lab for analysis. Finally, he will be asked to go to the Male Fertility Lab to provide a semen sample. Randomization: After the subject's urine culture results have been reviewed (patient must be free of urinary tract infection to be in study), the Investigational Pharmacy will be asked to randomize the patient. Pharmacy will then mail the patient's first month's study medication to him. He will also be mailed medication/voiding and pain diaries to fill out over the next month. Month Visit (Visit 2): The subject will return to the Urology Clinic about 1 month after his Screening Visit (Visit 1). He will first fill out follow-up forms. Next, his previous month's empty medication container and completed diaries will be collected. A pill count will then be done Finally, the subject will receive his second month's study medication and medication/voiding and pain diaries. Month Visit (Visit 3): Same as 1 Month Visit. Month Visit (Visit 4): First, the subject will be asked to fill out follow-up questionnaires Next, the patient's caregiver will perform a physical exam and prostate massage during which, expressed prostatic secretions will be collected. Then, his previous month's empty medication container and completed diaries will be collected. A pill count will then be done. Finally, the subject will be sent to the Male Fertility Lab to collect a semen sample (as in Screening Visit). 12 Month Visit (Visit 5): With the exception of pill count, etc., same as Visit 3. Dose: Active drug: Viagra, 50mg, orally, once a day, for 90 days Placebo: identically-appearing pill supplied by Pfizer Concurrent Therapy: _ No concurrent therapy will be offered

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostatitis
Keywords
Prostatitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
30 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Viagra (sildenafil citrate)
Primary Outcome Measure Information:
Title
NIH-CPSI -pain scores at 3 and 12 month post tx follow-up
Title
AUA Score - at 3 and 12 month post tx follow-up
Secondary Outcome Measure Information:
Title
Graded Chronic Pain Scale (GCPS)-3 & 12 mo post tx f/u

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of male Chronic Pelvic Pain Syndrome Type III Age 18 - 65 Pelvic pain duration of at least 3 months Exclusion Criteria: Urinary tract infection within the last year Sexually transmitted disease within 3 months Antiviral therapy or antibiotics within the last 3 months Currently taking any medications or recreational drugs containing nitrates 3A4 inhibitors such as erythromycin, ketoconazole, or itraconazole Alpha-blocker therapy for treatment of high blood pressure or prostate problems Suffered a heart attack, stroke or life-threatening arrhythmia within the last months Cardiac failure or coronary artery disease causing unstable angina Resting hypotension (BP<90/50) or hypertension (BP>170/110) Patients with retinitis pigmentosa Kidney, liver or blood problems (including sickle cell anemia or leukemia) Allergy to sildenafil Deformed penis, Peyronie's disease or ever having had an erection lasting more than 4 hours Stomach ulcers or any types of bleeding problems Use of any other medical treatments that cause erections: pills, medicines that are injected or inserted into the penis, implants or vacuum pumps Back pain, unilateral testicular pain or rectal pain only Post-surgical pain Prostate biopsy or cystoscopy within 3 months Pain from another source in the genital tract, such as kidney stones or neoplasm History of prostate, bladder, renal or other urinary malignancies History of intravesical Bacillus Calmette-Guerin (BCG) Ulcerative colitis or Crohn's disease Radiation therapy to pelvis History of genitourinary tuberculosis Any neurological abnormalities including spinal cord injury and stroke Overtly psychotic or suicidal Unable to understand the protocol In addition, subjects will be asked to refrain from having any new treatment for prostatitis during the study period, but will be allowed to remain on stable chronic therapy that they have been receiving for 3 or more months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard E Berger, MD
Organizational Affiliation
Professor of Urology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Washington, Urology Clinic
City
Seattle
State/Province
Washington
ZIP/Postal Code
09195
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III

We'll reach out to this number within 24 hrs